Atlas Trials

Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.

Clinical trial NCT01941329 · COMPLETED

Trial details

NCT number
NCT01941329
Sponsor
Association for Innovation and Biomedical Research on Light and Image
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
High Risk Proliferative Diabetic Retinopathy
Start date
2014-04-01
Primary completion
2016-04-01
Enrollment
94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.